Biomarkers for Predicting Mortality in Patients With Suspected Sepsis
The Use of Biomarkers for Predicting Mortality in Patients With Suspected Sepsis
1 other identifier
observational
250
1 country
1
Brief Summary
This retrospective study aimes to analyze the association of a number of routinely performed biomarkers with mortality in patients admitted to ICU with suspected sepsis. The study includes patients \>18 years of age, who had been admitted to the ICU with suspected sepsis. At ICU admission, baseline levels of PCT, CRP, albumin and lactate as well as WBC, neutrophil and lymphocyte counts will recorded.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2024
CompletedFirst Submitted
Initial submission to the registry
April 3, 2026
CompletedFirst Posted
Study publicly available on registry
April 9, 2026
CompletedApril 9, 2026
April 1, 2026
1.3 years
April 3, 2026
April 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
28-day mortality
mortality within 28 days after intensive care admission
28 days
Eligibility Criteria
The study population is patients older than 18 years of age who have primary diagnoses of admission to intensive care unit are infection and suspected sepsis.
You may qualify if:
- \>18 years of age
- admission to the ICU with suspected sepsis
You may not qualify if:
- ICU admission following cardiopulmonary resuscitation or cardiac surgery
- Having a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
- Interruption of the treatment process because of transfer to another healthcare facility
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Niğde Ömer Halisdemir University Training and Research Hospital
Niğde, Niğde Province, 51200, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sümeyye Uğur
Antalya Training and Research Hospital
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 3, 2026
First Posted
April 9, 2026
Study Start
May 1, 2023
Primary Completion
August 1, 2024
Study Completion
August 1, 2024
Last Updated
April 9, 2026
Record last verified: 2026-04